Clinical trials: Tumor Infiltrating Lymphocytes
Recurrent, Platinum-resistant
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating…
- Conditions
- Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT01883297
- Testing
- Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University Health Network, Toronto
Metastatic Melanoma
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Background: In a study in humans with melanoma, patients given total body irradiation to suppress the immune system in conjunction with chemotherapy showed a significant clinical response.
- Trial name
- NCT00314106
- Testing
- Melanoma Reactive TIL, Cyclophosphamide, IL-2
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy
- Trial name
- NCT04268108
- Testing
- liquid tumor infiltrating lymphocytes
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Triple-negative Breast Cancer
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Triple-negative breast cancer (TNBC) is a group of tumors that occurs mainly in young, premenopausal women and accounts for 10-20% of breast cancers.
- Trial name
- ETNA (NCT06078384)
- Testing
- Pembrolizumab 25 mg/ml, Paclitaxel injection
- Where
- 44 sites in France, Spain
- Volunteers
- 354 people
- Sponsor
- UNICANCER
Metastatic Triple Negative Breast Cancer
Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.
- Trial name
- NCT04111510
- Testing
- Tumor infiltrating lymphocytes (TIL) LN-145
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Glioma
Study of GC101 TIL in Brain Glioma (Soochow2)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v.
- Trial name
- NCT04943913
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Adult Gynecological Tumors
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors
This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:
- Trial name
- NCT06834542
- Testing
- Autologous tumor infiltrating lymphocyte injection（GT201）
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Grit Biotechnology
Triple Negative Breast Neoplasms, Triple Negative Breast Cancer
Triple-negative Breast Cancer: a New Perspective on Biomarkers
A single-institutional cohort to determine the prevalence of new immunohistochemical panel in advanced triple-negative submitted to neoadjuvant chemotherapy and its association with response and survival.
- Trial name
- TNBCbrazil (NCT03539965)
- Where
- Brazil
- Volunteers
- 239 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Advanced Solid Tumors
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.
- Trial name
- NCT06144671
- Testing
- GT201, IL-2, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Grit Biotechnology
Melanoma (Skin Cancer), Melanoma Metastatic
A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
The goal of this study is to determine the activity of Perkileucel, a tumour infiltrating lymphocyte (TIL) adoptive cell transfer therapy (ACT), in patients with unresectable stage III or metastatic melanoma who have progressed…
- Trial name
- PERTIL-01 (NCT07651618)
- Testing
- Tumour Infiltrating Lymphocytes Adoptive Cell Therapy, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Aldesleukin
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- East Metropolitan Health Service, Australia
Melanoma, Non Small Cell Lung Cancer
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
Background: The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- PragmaTIL (NCT06630611)
- Testing
- NMA-LD regimen, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Nasopharyngeal Carcinoma, Hepatocellular Carcinoma
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors
Background: T cell based adoptive immunotherapy including CTL and TIL may stimulated the immune system and stop cancer cells from growing.
- Conditions
- Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Breast Carcinoma
- Trial name
- NCT01462903
- Testing
- tumor infiltrating lymphocytes, IL-2
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC
This is a phase II clinical study testing a more personalized and lighter chemotherapy approach for women with stage I or II triple-negative breast cancer.
- Trial name
- DespaTIL (NCT07074106)
- Testing
- Carboplatin and a Taxane
- Where
- 5 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- D'Or Institute for Research and Education
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma
- Trial name
- NCT01174121
- Testing
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas
The purpose of this protocol is to determine whether autologous TIL infused in conjunction with systemic high-dose IL-2 after non-myeloablative chemotherapy with cyclophosphamide and fludarabine can cause consistent and durable…
- Trial name
- TIL (NCT02375984)
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Saint John's Cancer Institute
Non-Small Cell Lung Cancer
[18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer.
[18F]F-AraG is a promising tracer to image activated T-cells with positron emission tomography (PET). The aim of the ATTAIN trial is to investigate the pharmacokinetic characteristics of this novel tracer by performing a full…
- Trial name
- ATTAIN (NCT05157659)
- Testing
- [18F]F-AraG PET-scan
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Amsterdam UMC, location VUmc
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer
CISH Inactivated TILs in the Treatment of NSCLC
A clinical trial to assess the safety and efficacy of genetically-engineered Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- CheckCell-2 (NCT05566223)
- Testing
- Fludarabine, Cyclophosphamide, CISH Inactivated TIL
- Where
- 2 sites in United States
- Sponsor
- Intima Bioscience, Inc.
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor…
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00002733
- Testing
- aldesleukin, recombinant interferon alfa, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Breast Cancer, Treatment Side Effects
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy (GC 101 TIL) in patients with advanced breast cancer.
- Conditions
- Breast Cancer, Treatment Side Effects, Advanced Breast Cancer, Effects of Immunotherapy
- Trial name
- NCT05142475
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Metastatic Melanoma
TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
This is a two arm, open-labelled phase II randomised trial of Tumour Infiltrating Lymphocytes (TIL) in metastatic melanoma patients given with preconditioning chemotherapy and Interleukin-2 (IL2).
- Trial name
- METILDA (NCT01995344)
- Testing
- Cyclophosphamide, Fludarabine, Tumour Infiltrating Lymphocytes
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- The Christie NHS Foundation Trust